RAPID COMMUNICATION |
Correspondence to: Roderick A. Capaldi, Inst. of Molecular Biology, Univ. of Oregon, Eugene, OR 97403-1229. E-mail: rcapaldi@oregon.uoregon.edu
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Mitochondrial disorders can lead to a confusing array of symptoms, which frequently makes a diagnosis difficult. Traditional approaches to such diagnoses are based on enzyme activity assays, with further characterization provided by genetic analysis. However, these methods require relatively large sample sizes, are time-consuming, labor-intensive, and show variability between laboratories. Here, we report an immunocytochemical test that makes use of monoclonal antibodies to subunits from each of the oxidative phosphorylation complexes and pyruvate dehydrogenase to aid in the detection of mitochondrial disorders. It can be completed and data analyzed in less than 4 hr. We have used this test to study fibroblast cultures from patients with mitochondrial disorders arising from both mitochondrial DNA and nuclear DNA defects. We have also examined cases of Leigh syndrome arising from different genetic causes. We show that patients can be categorized on the basis of which complexes are affected and whether or not the defect being studied shows a mosaic distribution, an indicator of whether the causal mutation(s) is/are in the mitochondrial or nuclear genome. Immunocytochemical analysis as described here should be considered as an initial screen for mitochondrial disorders by which to direct (and limit) the subsequent enzymatic and genetic tests required to make an unambiguous diagnosis.
(J Histochem Cytochem 50:12811288, 2002)
Key Words: mitochondria, oxidative phosphorylation, immunocytochemistry, Leigh syndrome, pyruvate dehydrogenase, monoclonal antibodies
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Mitochondria play an essential role in the life of eukaryotic cells by carrying out many important metabolic activities, including producing the majority of the energy needed by the cells through oxidative phosphorylation (OX PHOS). Therefore, it is perhaps not surprising that mitochondrial dysfunction is a primary or secondary factor in many diseases, including multisystem metabolic disorders, diabetes, and neurodegenerative disorders (
Diagnosis of mitochondrial disorders can be complicated because of a confusing array of symptoms, the complex genetics, and the large number of proteins associated with these disorders. There are an estimated 87 different structural proteins that comprise the OX PHOS complexes alone and many other assembly and import factors required for the proper functioning of the OX PHOS system. Mitochondria also have their own DNA, which encodes 13 subunits of the OX PHOS complexes, 22 tRNAs, and two rRNAs. Therefore, disorders of mitochondrial function can stem from nuclear and/or mitochondrial DNA defects. Disorders stemming from mitochondrial DNA defects have added complexity in that the defect can be heteroplasmic. Although there are just two copies of each nuclear gene, every cell contains hundreds to thousands of copies of mitochondrial DNA and hence mitochondrion-encoded genes (-subunit of the pyruvate dehydrogenase (PDH) complex is encoded on the X-chromosome, and mutations in this gene are the most common causes of PDH deficiency (
Traditional approaches to the diagnosis of mitochondrial disorders have been based on enzymatic activity assays, with further characterization coming from genetic analysis. However, these methods require relatively large sample sizes and are time-consuming, labor-intensive, and are subject to variability from one laboratory to another. We therefore set out to devise a test that could be performed quickly on very small samples and that would aid in the diagnosis of mitochondrial disorders by identifying defective complexes for subsequent analysis by enzymatic and genetic methods. Here we report an immunocytochemical test that can be used to identify defects in which assembly of one or more of the five OX PHOS complexes or PDH is altered, which comprise the vast majority of cases. We demonstrate the utility of this test by studies of fibroblast cultures from patients with a range of mitochondrial disorders including nuclear and mitochondrial DNA defects. Four of the patients had Leigh syndrome, a rapidly progressing neurometabolic disorder that leads to degeneration of the central nervous system. The disease usually strikes young children between the ages of 3 months and 2 years, with death typically occurring within a few years. The genetic causes of Leigh syndrome are quite varied, with defects in complex I, complex II, complex IV, complex V, and PDH all having been reported to give rise to the disease (
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cell Lines
MRC5 fibroblasts were obtained from the American Type Culture Collection (Manassas, VA). Primary fibroblast cultures were obtained with consent from needle biopsies performed during diagnostic evaluations. The data presented in Table 1 on genetic cause and symptoms were obtained in the clinics at which the patients first presented. The various cell lines were provided as follows. Patient fibroblast cultures were obtained from the following sources. Patient 1 was from the Nijmegen Center for Mitochondrial Disorders (Nijmegen, The Netherlands). This patient has been described in
|
Antibodies
All antibodies were from Molecular Probes, Inc. (Eugene, OR). For specifics about each antibody see Table 2.
|
Immunocytochemistry
Fibroblasts were grown to 50% confluency on glass coverslips. The coverslips were removed from medium and washed in PBS before fixation in 4% paraformaldehyde for 20 min at room temperature (RT). Antigen retrieval was performed by submerging the coverslips in 100 mM Tris pH 9.5, 5% urea for 10 min at 95C. The coverslips were rinsed in PBS and placed in 0.1% Triton X-100 for 10 min at RT. Nonspecific antibody binding was blocked by placing the coverslips in 10% normal goat serum for 30 min at RT. Coverslips from each cell line were then exposed for 1 hr at RT to primary antibody cocktails consisting of anti-porin and one of each of the following antibodies: anti-complex I, 30-kD FeS protein; anti-complex II, 30-kD protein; anti-complex III, core 2; anti-complex IV-I, anti-complex IV-IV, anti-complex V, oligomycin sensitivity conferral protein (OSCP) or anti-pyruvate dehydrogenase E1
. Specific details of the isotype and concentration of each antibody used for immunocytochemistry are listed in Table 2. Coverslips were washed three times for 2 min each in PBS. Coverslips were then exposed for 45 min at RT to secondary antibody cocktails consisting of Alexa Fluor 594 goat anti-mouse IgG2b specific antibody (Molecular Probes) and either Alexa Fluor 488 goat anti-mouse IgG1 specific antibody (Molecular Probes, Inc.) (for the complex I, complex III, complex V, and PDH slides) or Alexa Fluor 488 goat anti-mouse IgG2a specific antibody (Molecular Probes) (for the complex II and complex IV slides). Coverslips were washed three times for 2 min in PBS before mounting in Vectashield Mounting Medium with DAPI (Vector Laboratories; Burlingame, CA). Results were imaged using a Nikon Eclipse E800 microscope (Nikon Instrument Group; Melville, NY) with a MicroMAX digital cooled CCD camera system (Princeton Instruments; Trenton, NJ).
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Patient Cell Lines Include Nuclear and mtDNA Mutations
In this study we compared the immunocytochemical characteristics of fibroblast cultures from eight patients in whom enzymatic deficiencies in either OX PHOS complexes or PDH had been confirmed. In six of these patients the pathogenic mutation had been identified genetically, but in two of the patients the genetic defect had not been identified. Four of the patients had heteroplasmic mitochondrial tRNA mutations giving rise either to mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) or to myoclonic epilepsy with ragged red fibers (MERRF). The other four patients had all been diagnosed with Leigh syndrome. Two of the patients showed complex IV deficiency, one of whom carried a mutation in an intron of the SURF-1 gene, which codes for a protein involved in complex IV assembly. Although the mutation occurred in an intron, we have previously shown that this cell line has undetectable levels of the Surf-1 protein by immunoblot (-subunit. Specifics for each patient are provided in Table 1.
A Rapid Immunocytochemical Approach to Identifying Defective OX PHOS Complexes
An important aim of the present study was to develop a screen for mitochondrial diseases that is rapid and that requires only small amounts of sample. For each of the eight patients, fibroblasts were cultured on six or seven glass coverslips. Analysis was performed before the cell cultures were confluent (4 x 105 cells per coverslip). Fibroblasts on each coverslip were immunostained with monoclonal antibody cocktails containing an antibody to porin as a control and an antibody to one each of the following proteins: complex I, 30-kD subunit; complex II, 30-kD FeS subunit; complex III, core 2 subunit; complex IV, subunit I; complex IV, subunit IV; complex V, OSCP. For patients 24, fibroblasts were also immunostained with an antibody cocktail containing antibodies to porin and to PDH-E1
-subunit. In cases where more than one immunocytochemically reactive monoclonal antibody (MAb) to a particular complex was available, the antibody showing the largest decrease in Western blots of patient cell lysates was chosen (data not shown). For complex IV, two different MAbs were used, because we expected that the mitochondrially encoded subunit I would show the largest decrease in staining for mitochondrial DNA defects but would be present, albeit in reduced amounts, in cell lines from patients with mutations in nuclear genes, particularly those with SURF-1 defects. A key aspect of the test is that the control antibody, porin, has a different isotype from all of the OX PHOS and PDH antibodies, so that each coverslip can be double stained by incubating the cells in a primary antibody cocktail followed by a incubation in an isotype-specific secondary antibody cocktail. Control experiments in which one of the primary antibodies was omitted showed no cross-label between the isotype-specific secondaries (data not shown). The double staining of cells serves as an internal control that helps to correct for intensity differences that may have been seen in single-labeled cells due to such things as variable thickness of cells or varying levels of mitochondrial mass between cells. Each step of the immunocytochemistry was analyzed to find the shortest time required while retaining good staining quality. The entire procedure can be completed and data obtained within 4 hr.
Patients 14 had all been diagnosed with Leigh syndrome, but with four different genetic causes of the disease represented among these patients (see Table 2). Immunocytochemical evaluation of these patient cell lines revealed which complex was defective in each case (Fig 1). Patient 1 had almost complete loss of staining for the complex I 30-kD subunit but normal staining for the other complexes. Patient 2 showed a uniform reduction in the levels of PDH-E1 staining, but normal staining of the other complexes. Patients 3 and 4 showed reduction in both complex IV-I and complex IV-IV staining but normal staining of the other complexes. Therefore, the immunocytochemical analysis was able to distinguish among different genetic causes of Leigh syndrome.
|
The Immunocytochemical Approach Reveals Mosaicism in mtDNA Defects
Patients 58 all had tRNA mutations resulting in a phenotype of either MELAS or MERRF. Immunocytochemical staining of these cell lines showed heterogeneous expression of complex I, III, and IV subunits. Some cells showed virtually no immunostaining, others had near normal levels, and still others had intermediate levels of staining. However, the two antibodies that revealed the highest proportion of affected cells were the complex I 30-kD antibody and the complex IV subunit I antibody. This is to be expected because complex I contains the largest number of mitochondrially encoded subunits and complex IV-subunit I is a mitochondrially encoded subunit. In addition, one of the MERRF cell lines (patient 8) showed heterogeneous expression of a complex II subunit. This was surprising because complex II is the only OX PHOS complex that has no mitochondrially encoded subunits. The number of cells showing reduced complex II staining was much smaller than the number of cells showing reduced complex I, III, or IV staining. Nevertheless, this suggests that complex II is downregulated in some cells with severely altered OX PHOS function as a consequence of mutations in other respiratory chain complexes.
Fig 2A shows the results for patient 8. The staining seen for complexes I, III, IV, and V for this patient is representative of the staining also seen in patients 57. The more normal pattern of staining of complex II is exemplified by patient 7 (Fig 2B). The heterogeneous staining patterns caused by the heteroplasmic expression of the tRNA mutations contrasts sharply with the uniform reduction of staining seen in cell lines from patients with nuclear DNA defects (Fig 1). In a situation in which the mutation is unknown, this difference is an important diagnostic clue. The mosaic expression of an OX PHOS subunit strongly suggests that a defect is mitochondrially encoded or involves a nucleus-encoded subunit that affects mtDNA copy number, as in mtDNA depletion patients (
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The clinical spectrum of mitochondrial disorders is quite diverse. Although there is growing awareness of the scope of these disorders, patients are often difficult to diagnose because the nature of the defect in individual cases is frequently poorly understood. Not only do the phenotypes of mitochondrial disorders vary greatly but the same phenotype can be caused by many different genetic defects, as is the case for Leigh syndrome. In addition, mutations in somatic nuclear, X-linked nuclear, and mitochondrial genes can all cause mitochondrial disorders, leading to a wide range of inheritance patterns. Therefore, methods that help to quickly identify the source of a defect are clearly needed if better treatment options for mitochondrial disorders are to be developed and to aid in genetic counseling.
Here we show that a simple immunocytochemical test can help to rapidly identify defective OX PHOS and PDH complexes. This test can be completed in less than 4 hr and requires minimal levels of sample, allowing the analysis to be performed shortly after the establishment of the primary cell cultures. Each sample is stained by two MAbs, one a control for mitochondrial mass (porin) and the second to identify the presence or absence of a particular complex.
To demonstrate the utility of this immunocytochemical analysis in pinpointing the nature of mitochondrial defects, we studied four patients who had been diagnosed with Leigh syndrome stemming from four different genetic causes. Our test was able to clearly differentiate among Leigh syndrome arising from a PDH defect, a complex I defect, and complex IV defects. Although Leigh syndrome affecting complex IV arising from a SURF-1 defect and a non-SURF-1 related defect could not be distinguished in this instance, previous reports have indicated that in many cases this may be possible. staining in all cells. However, females with PDH deficiencies should be mosaics, and this mosaicism is a valuable identifier that an individual is a carrier of a PDH defect even when major symptoms of PDH deficiency are not manifested (
As we show, an immunocytochemical analysis helps to distinguish between mitochondrial DNA defects and nuclear DNA defects. Two patients diagnosed with MELAS and two patients diagnosed with MERRF each showed a mosaic expression of OX PHOS subunits, as would be expected for a mitochondrial DNA mutation that was heteroplasmic. This type of staining pattern is quite different from that observed in cell lines carrying a somatic nuclear mutation, which shows a uniform reduction of a subunit in all of the cells. A heterogeneous staining pattern, when observed for multiple OX PHOS complexes, is an important indicator of a mitochondrial DNA defect and points to a mutation in a mitochondrially encoded tRNA or rRNA or a large-scale mitochondrial DNA deletion as the likely cause, or to a mitochondrial DNA depletion syndrome, which is much rarer.
In summary, we provide a simple, rapid immunocytochemical test by which to detect defects in the OX PHOS complexes or PDH. These defects account for the majority of mitochondrial disorders. Because this test is quick, relatively easy to perform, and requires very small sample volumes, we believe that it complements the current mitochondrial diagnostic tests available by focusing attention on the proteins that are defective and thereby directing and greatly limiting the number of biochemical and genetic analyses that must be performed for an unequivocal diagnosis.
Received for publication May 30, 2002; accepted July 3, 2002.
![]() |
Literature Cited |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Carrozzo R, Tessa A, VazquezMemije ME, Piemonte F, Patrono C, Malandrini A, DionisiVici C et al. (2001) The T9176G mtDNA mutation severely affects ATP production and results in Leigh syndrome. Neurology 56:687-690
Dahl HH (1998) Getting to the nucleus of mitochondrial disorders: identification of respiratory chain-enzyme genes causing Leigh syndrome. Am J Hum Genet 63:1594-1597[Medline]
Hanson BJ, Carrozzo R, Piemonte F, Tessa A, Robinson BH, Capaldi RA (2001) Cytochrome c oxidase-deficient patients have distinct subunit assembly profiles. J Biol Chem 276:16296-16301
Leonard JV, Schapira AHV (2000) Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet 355:299-304[Medline]
Lib MY, Brown RM, Brown GK, Marusich MF, Capaldi RA (2002) Detection of pyruvate dehydrogenase complex deficiencies in females by an immunohistochemical quantitation of mosaicism in patient fibroblast cell lines. J Histochem Cytochem 50:877-884
Lissens W, De Meirleir L, Seneca S, Liebaers I, Brown GK, Brown RM, Ito M et al. (2000) Mutations in the X-linked pyruvate dehydrogenase (E1) alpha subunit gene (PDHA1) in patients with a pyruvate dehydrogenase complex deficiency. Hum Mutat 15:209-219[Medline]
Marusich MF, Robinson BH, Taanman J-W, Kim SJ, Schillace R, Smith JL, Capaldi RA (1997) Expression of mtDNA and nDNA encoded respiratory chain proteins in chemically and genetically-derived Rho0 human fibroblasts: a comparison of subunit proteins in normal fibroblasts treated with ethidium bromide and fibroblasts from a patient with mtDNA depletion syndrome. Biochim Biophys Acta 1362:145-159[Medline]
Munnich A, Rustin P, Rötig A, Chretien D, Bonnefont JP, Nuttin C, Cormier V et al. (1992) Clinical aspects of mitochondrion disorders. J Inher Metab Dis 15:448-455[Medline]
Pon LA, Schon EA (2001) Methods in Cell Biology. Vol. 65 Mitochondria. San Diego, Academic Press, pp. 454455
Sheffler IE (1999) Mitochondria. 1st ed New York, Wiley
Triepels RH, Hanson BJ, van den Heuvel LPWJ, Sundell L, Marusich MF, Smeitink JAM, Capaldi RA (2001) Human complex I defects can be resolved by monoclonal antibody analysis into distinct subunit assembly patterns. J Biol Chem 276:8892-8897
Williams SL, Scholte HR, Gray RGF, Leonard JV, Schapira AHV, Taanman J-W (2001) Immunological phenotyping of fibroblast cultures from patients with a mitochondrial respiratory chain deficit. Lab Invest 81:1069-1077[Medline]
Zhuchenko O, Wehnert M, Bailey J, Sun ZS, Lee CC (1996) Isolation, mapping, and genomic structure of an X-linked gene for a subunit of human mitochondrial complex I. Genomics 37:281-288[Medline]